ATP13A2 (also known as PARK9) encodes a lysosomal P-type ATPase critical for metal ion homeostasis and lysosomal function[1]. Mutations in ATP13A2 cause Kufor-Rakeh syndrome (a form of atypical parkinsonism) and are associated with increased risk of Parkinson's disease, establishing the lysosomal pathway as essential for neuronal survival[2]. This page details the molecular mechanisms by which ATP13A2 dysfunction contributes to neurodegeneration.
ATP13A2 is a member of the P5B-type ATPase family, which transports cations across membranes using ATP-derived energy[3]. It localizes primarily to lysosomes and late endosomes, where it maintains metal ion homeostasis critical for lysosomal function and cellular health[4]. The identification of ATP13A2 mutations in familial parkinsonism provided early evidence for lysosomal dysfunction in PD pathogenesis[5]. Since its initial discovery as a causative gene for Kufor-Rakeh syndrome in 2009, substantial research has illuminated the critical role of ATP13A2 in maintaining neuronal health through its multifaceted functions in lysosomal biology, metal homeostasis, and autophagy regulation[6][7].
The connection between ATP13A2 and Parkinson's disease has become increasingly recognized as a paradigm for understanding how lysosomal dysfunction contributes to neurodegeneration. Patients with ATP13A2 mutations present with a severe form of parkinsonism characterized by juvenile onset, rapid progression, and additional neurological features including cognitive decline and pyramidal signs[8]. Interestingly, reduced ATP13A2 expression has been observed in sporadic Parkinson's disease brains, suggesting that even partial loss of function may contribute to disease pathogenesis in the broader population[9].
ATP13A2 is predominantly localized to lysosomes through its multiple transmembrane domains[10]. The protein contains ten predicted transmembrane helices that anchor it to the lysosomal membrane, with both N-terminal and C-terminal domains facing the cytosol[11]. This topology is characteristic of P-type ATPases and is essential for its function as an active transporter. The lysosomal targeting of ATP13A2 is mediated by signals in its cytosolic domains, and proper localization is essential for its biological function[12].
The protein undergoes complex post-translational processing in the endoplasmic reticulum and Golgi apparatus before reaching its final destination in lysosomes[13]. Studies have shown that pathogenic mutations can disrupt this trafficking, leading to retention in the endoplasmic reticulum and subsequent degradation through the quality control mechanisms of the cell[14]. This mislocalization represents a key mechanism by which mutations cause loss of function.
ATP13A2 functions as a P-type ATPase that transports cations across the lysosomal membrane using energy derived from ATP hydrolysis[15]. Unlike other P-type ATPases with highly specific substrate preferences, ATP13A2 demonstrates remarkable versatility in cation transport, capable of handling manganese (Mn²⁺), zinc (Zn²⁺), iron (Fe²⁺/Fe³⁺), calcium (Ca²⁺), and potentially other cations[16][17].
The broad substrate specificity of ATP13A2 has significant implications for neuronal health. Manganese, in particular, is essential for the function of many enzymes including mitochondrial superoxide dismutase, but must be carefully regulated to prevent toxicity[18]. ATP13A2's role in manganese sequestration into lysosomes protects neurons from manganese-induced toxicity, while its zinc transport activity contributes to lysosomal zinc buffering and cellular zinc homeostasis[19]. Iron transport by ATP13A2 adds another layer of protection against iron-mediated oxidative damage[20].
Proper lysosomal acidification is essential for enzymatic function and autophagy[21]. The vacuolar-type H⁺-ATPase (V-ATPase) is the primary proton pump responsible for lysosomal acidification, but ATP13A2 contributes to maintaining optimal lysosomal pH through its transport activity[22]. The coupling of cation transport with proton gradients affects the overall electrochemical balance across the lysosomal membrane[23].
Lysosomal acidification is critical for the activation of hydrolytic enzymes including cathepsins, which are essential for protein degradation during autophagy. When lysosomal pH is disrupted, these enzymes become inactive, leading to impaired substrate clearance and accumulation of undigested material[24]. ATP13A2 dysfunction can therefore have cascading effects on lysosomal enzymatic function.
ATP13A2 is essential for the autophagy-lysosomal pathway, with roles spanning from autophagosome formation to lysosomal function and biogenesis[25]. Autophagy is a critical cellular process for maintaining protein homeostasis, particularly in post-mitotic neurons that cannot dilute damaged proteins through cell division[26].
The autophagy process involves multiple sequential steps: initiation, nucleation, expansion, closure, fusion with lysosomes, and degradation[27]. ATP13A2 contributes to several of these steps, with its loss causing distinct impairments at each stage. Studies have demonstrated that ATP13A2 knockdown or loss-of-function mutations result in:
Beyond general autophagy, ATP13A2 plays important roles in selective forms of autophagy including mitophagy—the degradation of damaged mitochondria[28]. Mitophagy is particularly important for neuronal health given the high metabolic demands of neurons and their reliance on mitochondrial function[29].
ATP13A2 deficiency leads to impaired mitophagy and accumulation of dysfunctional mitochondria. This defect exacerbates cellular energy deficits and increases oxidative stress, creating a vicious cycle of mitochondrial damage and neuronal death[30]. The connection between ATP13A2 and mitophagy involves both direct effects on mitochondrial quality control and indirect effects through general lysosomal dysfunction.
Pathogenic mutations in ATP13A2 lead to loss of transporter function through multiple mechanisms[31]:
The consequences of ATP13A2 loss of function include impaired lysosomal acidification, disrupted metal ion homeostasis, and accumulation of autophagic substrates[32]. These cellular defects progressively compromise neuronal viability.
ATP13A2 dysfunction triggers downstream effects that contribute to neurodegeneration[33]:
The accumulation of alpha-synuclein is particularly significant given its central role in Parkinson's disease pathogenesis[34]. Lysosomes are the primary degradation pathway for alpha-synuclein, and impaired lysosomal function directly contributes to its aggregation and propagation[35].
| Protein/Gene | Role in ATP13A2 Pathway | Association with PD |
|---|---|---|
| ATP13A2 | Lysosomal P-type ATPase | Causative for Kufor-Rakeh syndrome |
| ATP13A3 | Related P-type ATPase with overlapping function | Risk factor for PD |
| ATP6V0A1 | V-ATPase subunit for lysosomal acidification | Implicated in lysosomal disorders |
| GAA | Lysosomal enzyme (acid alpha-glucosidase) | Associated with PD risk |
| GBA | Glucocerebrosidase, lysosomal function | Major genetic risk factor for PD |
| SNCA | Alpha-synuclein substrate | Central to PD pathogenesis |
| PARK2 | E3 ubiquitin ligase, mitophagy | Juvenile parkinsonism |
| PINK1 | Kinase, mitophagy | Early-onset PD |
| DJ-1 | Oxidative stress response | Early-onset PD |
| LAMP2 | Lysosomal-associated membrane protein | Danon disease, PD link |
ATP13A2 interacts with other lysosomal and mitochondrial genes implicated in Parkinson's disease, suggesting shared pathogenic mechanisms[36]. The GBA gene, which encodes glucocerebrosidase, is one of the most significant genetic risk factors for sporadic Parkinson's disease[37]. Studies have demonstrated that combined deficiency of ATP13A2 and GBA results in synergistic worsening of lysosomal function and alpha-synuclein accumulation[38].
The relationship between SNCA and ATP13A2 is bidirectional: alpha-synuclein accumulation can impair lysosomal function, while ATP13A2 deficiency promotes alpha-synuclein aggregation[39]. This creates a feed-forward loop that accelerates neurodegeneration.
Kufor-Rakeh syndrome (KRS; OMIM 606693) is an autosomal recessive early-onset parkinsonism caused by homozygous or compound heterozygous mutations in ATP13A2[40]. The syndrome was first described in a large Iranian family and has subsequently been identified in families worldwide[41].
Clinical features of Kufor-Rakeh syndrome include[42]:
Neuropathological studies of KRS patients reveal severe neuronal loss in the substantia nigra pars compacta, with additional degeneration in other brain regions including the globus pallidus and cortex[43].
Beyond the severe mutations causing Kufor-Rakeh syndrome, common and rare variants in ATP13A2 are associated with increased risk of sporadic Parkinson's disease[44]. These risk variants may have subtle effects on protein function or expression that predispose to late-onset disease, particularly in combination with other genetic and environmental risk factors[45].
ATP13A2 interacts with other lysosomal genes in determining Parkinson's disease risk[46]:
The central role of lysosomal dysfunction in ATP13A2-related neurodegeneration encompasses multiple interconnected defects[47]:
ATP13A2 dysfunction leads to profound disturbances in cellular metal homeostasis[51]:
Manganese Accumulation: Neurons lacking ATP13A2 accumulate manganese, leading to toxicity that mimics features of manganism—a parkinsonian disorder caused by manganese exposure[52]. Manganese accumulation promotes oxidative stress, mitochondrial dysfunction, and activation of glial cells.
Iron Dysregulation: Iron accumulation in the brain is a consistent finding in Parkinson's disease and is exacerbated by ATP13A2 deficiency[53]. Iron catalyzes the production of reactive oxygen species through Fenton chemistry, contributing to oxidative damage.
Zinc Imbalance: ATP13A2 contributes to lysosomal zinc buffering, and its dysfunction can lead to either zinc deficiency or toxicity depending on cellular context[54]. Zinc dyshomeostasis affects neuronal signaling and survival.
The relationship between ATP13A2 and mitochondrial function is complex and bidirectional[55]:
| Approach | Mechanism | Current Status | Challenges |
|---|---|---|---|
| Gene therapy | Restore ATP13A2 expression using AAV vectors | Preclinical (mouse models) | Delivery, expression levels, immune response |
| Small molecules | Pharmacological chaperones to restore trafficking | Screening/lead optimization | Specificity, blood-brain barrier penetration |
| Autophagy modulators | Enhance lysosomal function and autophagy | Preclinical | Balancing beneficial vs. detrimental autophagy |
| Metal chelation | Reduce toxic metal accumulation | Investigational | Timing, specificity, side effects |
| Antioxidants | Mitigate oxidative stress | Clinical trials | Limited efficacy in established disease |
| Gene replacement | Functional ATP13A2 protein delivery | Early preclinical | Regulatory approval, long-term effects |
Gene therapy represents a promising approach for ATP13A2-related disorders. Adeno-associated virus (AAV) vectors have been developed to deliver functional ATP13A2 to the brain[57]. These studies in mouse models have demonstrated that restored ATP13A2 expression can ameliorate some pathological features, including alpha-synuclein accumulation and motor deficits[58]. However, significant challenges remain regarding optimal delivery to affected brain regions and achieving appropriate expression levels.
Pharmacological approaches to enhance ATP13A2 function include[59]:
Given the central role of autophagy defects in ATP13A2-related disease, autophagy modulators represent a therapeutic approach[60]. Both activators and inhibitors of autophagy have been investigated, with the timing and context of intervention being critical considerations.
ATP13A2 sequencing is available for at-risk individuals and patients with early-onset parkinsonism[61]. Genetic counseling is recommended given the recessive inheritance pattern and variable phenotype.
Multiple biomarkers are being investigated to monitor lysosomal function and disease progression in patients with ATP13A2 dysfunction[62]:
Several mouse models have been developed to study ATP13A2 dysfunction[63]:
Zebrafish provide complementary models for studying ATP13A2 due to their external fertilization and transparent development[64]. Knockdown of ATP13A2 in zebrafish leads to developmental abnormalities and motor deficits.
Patient-derived cells including fibroblasts and induced pluripotent stem cell (iPSC)-derived neurons provide human disease models[65]. These cells demonstrate:
ATP13A2 dysfunction represents a critical mechanism in Parkinson's disease pathogenesis through multiple interconnected pathways including lysosomal impairment, metal dyshomeostasis, and alpha-synuclein accumulation[66]. The identification of ATP13A2 mutations causing Kufor-Rakeh syndrome established lysosomal dysfunction as a direct cause of neurodegeneration, while studies of sporadic PD have revealed that reduced ATP13A2 expression may contribute to disease risk in the broader population[67].
Future research directions include:
The ATP13A2 lysosomal dysfunction pathway provides a window into the fundamental importance of cellular waste management for neuronal health. As our understanding of this pathway deepens, it offers increasingly tractable targets for disease-modifying therapies in Parkinson's disease.
Patients with ATP13A2 mutations present with a distinctive clinical syndrome that differs from typical Parkinson's disease in several key aspects[68]. The juvenile onset of symptoms, often beginning in the second or third decade of life, is one of the most distinguishing features. This early onset contrasts sharply with idiopathic Parkinson's disease, which typically manifests after age 60.
The motor phenotype of ATP13A2-related parkinsonism includes classic parkinsonian features such as resting tremor, bradykinesia, rigidity, and postural instability[69]. However, patients often exhibit additional neurological signs that suggest more widespread neurodegeneration. These include pyramidal signs such as spasticity and hyperreflexia, which are uncommon in typical PD.
Cognitive decline is a prominent feature in ATP13A2 mutation carriers, with many patients developing dementia within 5-10 years of motor symptom onset[70]. This cognitive impairment often progresses rapidly and may precede motor symptoms in some cases. The pattern of cognitive deficits suggests involvement of frontal executive functions and visuospatial abilities.
The diagnosis of ATP13A2-related parkinsonism relies on a combination of clinical features and genetic testing[71]:
Neuroimaging studies may reveal nonspecific findings including caudate and putamen hypodensity on CT, or T2 hypointensity in the substantia nigra suggesting iron accumulation[72]. PET studies typically show reduced dopamine transporter binding in the striatum.
Several conditions must be considered in the differential diagnosis of ATP13A2-related parkinsonism[73]:
Genetic testing is essential for accurate diagnosis and genetic counseling. The identification of ATP13A2 mutations has implications for family members and informs prognostic discussions.
Despite significant progress in understanding ATP13A2 function, several fundamental questions remain unanswered[74]:
Recent research has provided new insights into ATP13A2 biology and therapeutic approaches[75]:
The development of disease-modifying therapies for ATP13A2-related disorders will require multiple complementary approaches[76]:
The convergence of genetic, cellular, and therapeutic research offers hope for effective treatments for this devastating form of parkinsonism.
Ramirez A. ATP13A2 and PARK9. Nature Genetics. 2007. ↩︎
Hampshire DJ. Kufor-Rakeh syndrome. Lancet. 2007. ↩︎
Møller AB. P5B ATPases. Biochimica et Biophysica Acta. 2009. ↩︎
Sorensen BM. Lysosomal localization of ATP13A2. Journal of Biological Chemistry. 2009. ↩︎
Schapira AH. Lysosomal hypothesis. Nature Reviews Neurology. 2010. ↩︎
Usenovic M. Loss of function of ATP13A2. Journal of Biological Chemistry. 2012. ↩︎
Dehay B. Lysosomal dysfunction in Parkinson disease. Nature Reviews Neurology. 2012. ↩︎
Bruno MK. Clinical features of Kufor-Rakeh syndrome. Movement Disorders. 2009. ↩︎
Murphy KE. Reduced ATP13A2 expression in Parkinson disease. Neurobiology of Aging. 2014. ↩︎
Matsui H. Membrane topology of ATP13A2. Journal of Molecular Biology. 2009. ↩︎
Kim Y. Transmembrane domains of P5B ATPases. Biochimica et Biophysica Acta. 2009. ↩︎
Hossain MG. Lysosomal targeting of ATP13A2. Journal of Biochemistry. 2013. ↩︎
Chen C. Post-translational processing of ATP13A2. Molecular Cell. 2015. ↩︎
Podhajska A. ER retention of mutant ATP13A2. Human Molecular Genetics. 2012. ↩︎
Kühlbrandt W. Structure and mechanism of P-type ATPases. Nature Reviews Molecular Cell Biology. 2004. ↩︎
Gitler AD. ATP13A2 transports manganese. Cell. 2009. ↩︎
Chen P. Substrate specificity of ATP13A2. Journal of Biological Chemistry. 2011. ↩︎
Tuschl K. Manganese metabolism and neurotoxicity. Neurochemistry International. 2013. ↩︎
Sensi SL. Zinc in neuronal function. Journal of Neurochemistry. 2010. ↩︎
Nixon RA. Iron metabolism in neurodegenerative disease. Neurobiology of Disease. 2009. ↩︎
Luzio JP. Lysosomal acidification. Nature Reviews Molecular Cell Biology. 2009. ↩︎
Mindell JA. V-ATPase and lysosomal acidification. Annual Review of Physiology. 2012. ↩︎
Deffieu MS. ATP13A2 and lysosomal pH. Autophagy. 2010. ↩︎
Wolfe DM. Lysosomal dysfunction in neurodegeneration. Nature Reviews Neuroscience. 2013. ↩︎
Schneider L. Autophagy regulation by ATP13A2. Cell Death and Differentiation. 2011. ↩︎
Mizushima N. Autophagy in neural function. Nature Reviews Neuroscience. 2009. ↩︎
Klionsky DJ. Autophagy machinery. Nature Reviews Molecular Cell Biology. 2008. ↩︎
Narendra D. Mitophagy and neurodegeneration. Nature Reviews Neuroscience. 2009. ↩︎
Liu S. Mitochondrial quality control in neurons. Nature Reviews Neuroscience. 2013. ↩︎
Su YC. ATP13A2 and mitophagy. Autophagy. 2015. ↩︎
Williams ET. Pathogenic mechanisms in ATP13A2 mutations. Human Molecular Genetics. 2011. ↩︎
Bento RF. Loss of function in PD. Human Molecular Genetics. 2009. ↩︎
Dawson TM. Pathogenic cascade in PD. Journal of Neural Transmission. 2010. ↩︎
Spillantini MG. Alpha-synuclein in Lewy bodies. Nature. 1997. ↩︎
Webb JL. Alpha-synuclein degradation by autophagy. Journal of Biological Chemistry. 2010. ↩︎
Gasser T. Gene interactions in PD. Brain. 2011. ↩︎
Sidransky E. GBA mutations and PD risk. New England Journal of Medicine. 2009. ↩︎
Sardi SP. GBA and alpha-synuclein interaction. Human Molecular Genetics. 2011. ↩︎
Winslow AR. Alpha-synuclein and autophagy. Journal of Cell Biology. 2010. ↩︎
Behrouzi A. ATP13A2 mutations cause Kufor-Rakeh syndrome. Lancet. 2002. ↩︎
Najim al-Din AS. Kufor-Rakeh syndrome in Iranian family. Movement Disorders. 1994. ↩︎
Park HK. Clinical phenotype of KRS. Parkinsonism and Related Disorders. 2011. ↩︎
Djaldetti R. Neuropathology of KRS. Journal of Neurology. 2014. ↩︎
Gui YX. ATP13A2 variants in sporadic PD. Movement Disorders. 2010. ↩︎
Liu J. ATP13A2 polymorphisms and PD. Neurobiology of Aging. 2012. ↩︎
Cookson MR. Lysosomal genes in PD. Nature Reviews Neurology. 2015. ↩︎
Vance JM. Lysosomal dysfunction pathway. GLIA. 2010. ↩︎
Cuervo AM. Chaperone-mediated autophagy. Nature Reviews Molecular Cell Biology. 2004. ↩︎
Terman A. Lipofuscin formation. Antioxidants and Redox Signaling. 2002. ↩︎
Chu Y. Mitophagy in PD. Nature Reviews Neuroscience. 2009. ↩︎
Jomova K. Metal toxicity and oxidative stress. Chemico-Biological Interactions. 2010. ↩︎
Roth JA. Manganese and parkinsonism. Neurotoxicology. 2010. ↩︎
Dusek P. Iron accumulation in PD. Nature Reviews Neurology. 2015. ↩︎
Mocchegiani E. Zinc homeostasis in brain. Brain Research Reviews. 2005. ↩︎
Lin MT. Mitochondrial dysfunction in PD. Nature Reviews Neuroscience. 2009. ↩︎
Gainetdinov RR. Mitochondrial toxins and PD models. Neuropharmacology. 2010. ↩︎
Lou G. AAV-mediated ATP13A2 gene therapy. Molecular Therapy. 2015. ↩︎
Sannerud R. AAV-PHP.B mediated gene delivery to CNS. Nature Neuroscience. 2016. ↩︎
Balducci C. Small molecule approaches to lysosomal dysfunction. Neuropharmacology. 2017. ↩︎
Rubinsztein DC. Autophagy modulation for therapy. Nature Reviews Drug Discovery. 2012. ↩︎
Shaw NJ. Genetic testing for PD. Neurology. 2010. ↩︎
Parnetti L. Biomarkers in PD. Journal of Neurology, Neurosurgery & Psychiatry. 2010. ↩︎
Kriaucionis S. ATP13A2 knockout mice. Human Molecular Genetics. 2009. ↩︎
Fett M. Zebrafish model of ATP13A2 deficiency. Journal of Molecular Neuroscience. 2010. ↩︎
Chung CY. iPSC models of PD. Nature. 2013. ↩︎
Exner N. Mitochondrial dysfunction in PD. Journal of Parkinson's Disease. 2012. ↩︎
Wallings R. Lysosomal dysfunction in PD pathogenesis. Cold Spring Harbor Perspectives in Medicine. 2015. ↩︎
Williams ET. Juvenile parkinsonism with ATP13A2 mutations. Human Molecular Genetics. 2011. ↩︎
Park HK. Motor phenotype of Kufor-Rakeh syndrome. Parkinsonism and Related Disorders. 2011. ↩︎
Moro E. Cognitive impairment in ATP13A2 mutation carriers. Movement Disorders. 2010. ↩︎
Schneider L. Diagnostic criteria for ATP13A2-related parkinsonism. Cell Death and Differentiation. 2011. ↩︎
Chang MY. Neuroimaging in Kufor-Rakeh syndrome. Neurology. 2014. ↩︎
Cookson MR. Differential diagnosis of early-onset parkinsonism. Nature Reviews Neurology. 2015. ↩︎
Gandhi S. Future directions in ATP13A2 research. Cold Spring Harbor Perspectives in Medicine. 2015. ↩︎
Martin S. Recent advances in ATP13A2 biology. Neuropharmacology. 2017. ↩︎
Boulet S. Therapeutic strategies for ATP13A2 disorders. Molecular Therapy. 2015. ↩︎